Speakers

Expand/Collapse

Charles Cheung
Senior Scientist
Abbvie

Day Two

Thursday 24 September, 2020

9:30 am | RSL-DVDs: An Improved Disulfide-Reinforced Single Linker DVD-Ig Bispecific Format

Paul Widboom
Associate Director
Adimab LLC

Pre-Conference Focus Day

12:15 pm | Discovering the Balance Between Safety & Efficacy

Joachim Koch
Head of Translational Research & Innovation
Affimed GmbH

Pre-Conference Focus Day

10:15 am | Affimed’s Bispecific Innate Cell Engagers: Activating CD16A for Tumor Cell Killing

Jonathan Lai
Associate Professor - Biochemistry
Albert Einstein College of Medicine

Christina Furebring
Vice President - Research & Development
Alligator Bioscience AB

Colleen Steinmeyer
Scientist
Amgen

Matthew Chun
Scientist
Amgen

John Delaney
Executive Director - Research
Amgen Inc.

Ryan Potts
Cell & Molecular Biology, Associate Member, St. Jude Faculty
Amgen/St Jude Children’s Research Center

Day Two

Thursday 24 September, 2020

4:15 pm | Small Molecule Bispecifics for Targeted Protein Degradation

Jane Gross
Senior Vice President & Chief Scientific Officer
Aptevo Therapeutics Inc.

Changshou Gao
Senior Director and Fellow (R&D)
AstraZeneca

Amrik Basran
Chief Scientific Officer
Avacta Group Plc

Day Two

Thursday 24 September, 2020

9:00 am | Affimer Therapeutics: A Versatile Antibody Mimetic Platform for the Generation of Bispecific Immunotherapies

Rebecca Williams
Senior Analyst
Beacon

Day One

Wednesday 23 September, 2020

9:00 am | Review of the Bispecific Landscape

Eugene Zhukovsky
Chief Scientific Officer - Research
Biomunex Pharmaceuticals

Day Two

Thursday 24 September, 2020

4:45 pm | Panel Discussion: Examining Trends & Future Opportunities in this Rapidly Evolving Space - What Does the Future of the BioSpecific Look Like?

10:00 am | Panel Discussion: Demonstrating the Superiority of Bispecifics in Immuno-Oncology Indications in Comparison with Antibody Combinations

Rakesh Dixit
President & Chief Executive Officer
Bionavigen

Pre-Conference Focus Day

9:00 am | Learning from Successful & Failed Bispecific Biologics

Steven Chamow
President
Chamow & Associates Inc.

James Legg
Senior Vice President - Research Research & Development
Crescendo Biologics

Pre-Conference Focus Day

2:45 pm | T-cell Enhancers for Focused CD137/4-1BB Co-Stimulation in the Tumour Microenvironment

Stephanie Truhlar
Senior Research Advisor, AME/Biotechnology Discovery Research
Eli Lilly and Company

Day Two

Thursday 24 September, 2020

2:15 pm | Methods for Obtaining Manufacturable IgG Bispecific Antibodies

Seema Kumar
Associate Director
EMD Serono

Pre-Conference Focus Day

11:15 am | Key Considerations for Drug Disposition Strategies for Bispecific Antibodies

Ambrose Williams
Scientist, Tech Dev
Genentech

Vittal Shivva
Scientist
Genentech

Rick Austin
Senior Director
Harpoon Therapeutics Inc.

Pre-Conference Focus Day

1:45 pm | TriTACs Are T-cell Engaging Drugs for Treatment of Solid Tumors

Wayne Godfrey
Vice President - Clinical Development
IGM Biosciences

Horacio Nastri
Executive Director
Incyte Corporation

Day Two

Thursday 24 September, 2020

10:00 am | Panel Discussion: Demonstrating the Superiority of Bispecifics in Immuno-Oncology Indications in Comparison with Antibody Combinations

Pre-Conference Focus Day

9:30 am | Panel Discussion: Contrasting Bispecific Therapeutics & CAR-T Approaches

Junjian Liu
Vice President - Biologics Discovery
Innovent Biologics, Inc.

Jonathan Davis
Head, Innovation
Invenra Inc.

Indrajeet Singh
Principal Scientist
Johnson & Johnson

Paul Moore
Vice President - Cell Biology & Immunology
MacroGenics

Chad May
Senior Vice President - Research & Development
Maverick Capital

Day Two

Thursday 24 September, 2020

2:45 pm | 5 Protease Dependent COBRA™ Activity Regresses Established Solid Tumors in Mice

Kalyan Pande
Associate Principal Scientist, Biologics Discovery
Merck & Co

Wilfred Marissen
Senior Director, Product Developmet
Merus

Mark Throsby
Chief Scientific Officer and Executive Vice President,
Merus NV

Day Two

Thursday 24 September, 2020

5:30 pm | Triclonics™ Engagers: Multi-specific Common Light Chain Antibodies Discovered by Unbiased Functional Screening

Niina Veitonmaki
Director - In Vivo Immune-Oncology & Head of in Vivo Core
Molecular Partners AG

Day Two

Thursday 24 September, 2020

3:45 pm | Novel Therapeutic Design of Tumor-targeted CD40 Agonistic DARPin® Molecule Leads to Antitumor Activity with Limited Systemic Toxicity

Nimish Gera
Co-Founder & Director - Research & Development
Mythic Therapeutics

John Blankenship
Senior Investigator & Group Leader - Antibody Discovery
Novartis

Day One

Wednesday 23 September, 2020

9:30 am | Panel Discussion: Solving the Specificity Problem to Pioneer Bispecifics in Solid Tumor Indications

Day Two

Thursday 24 September, 2020

4:45 pm | Panel Discussion: Examining Trends & Future Opportunities in this Rapidly Evolving Space - What Does the Future of the BioSpecific Look Like?

Adam Root
Senior Principal Scientist
Pfizer

Pre-Conference Focus Day

2:15 pm | 5 Discovery & Optimization of T-cell Bispecifics for the Treatment of Solid Tumors

Mohamed Elmeliegy
Associate Director - Clinical Pharmacology
Pfizer

Pre-Conference Focus Day

4:30 pm | Chair’s Closing Remarks

3:45 pm | Panel Discussion: Evaluating the Criteria Essential to Success in the Increasingly Competitive CD3 Bispecific Field

11:45 am | An Industry Perspective on CD3 Bispecifics Starting Doses & Efficacious Dose Projections

Kara Olson
Senior Staff Scientist
Regeneron Pharmaceuticals

Day One

Wednesday 23 September, 2020

10:15 am | Development of Novel Fully Human Bispecific Antibodies for Oncology

Aynur Hermann
Director, Therapeutic Proteins
Regeneron Pharmaceuticals

Jasmin Sydow-Andersen
Senior Scientist / Lab Head Mass Spectrometry
Roche

Fateme Tousi
Scientist
Sanofi

Zhi-yong Yang
Director - Research & Development
Sanofi

Wei Yan
Yan President & CEO
Sound Biologics

Nathan Trinklein
Chief Technology Officer
TeneoBio

Rastislav Tamaskovic
Researcher
University Medical Center Groningen

Andrew Tsourkas
Professor of Bioengineering
University of Pennsylvania

Jeffrey Way
Senior Staff Scientist
Wyss Institute at Harvard University

Arthur Chirino
Senior Director, Product Control Strategy & Manufacturing
Xencor

Rupert Davies
Director, Pharmacokinetics
Zymeworks